Last week you covered how the new Omicron boosters were raced through the FDA's EUA process

and now being put out into the public on basically the strength of a study of eight mice that was public.

And no human trials, no human data essentially. Let's check in from that time till now and see

how the public messaging is going. Take a listen to Dr. Fauci. When you have a updated vaccine

that serves as a boost as it were and is directed against the dominant circulating strain that's in society,

you have every reason to believe that that is going to be better than having a vaccine that isn't

highly specific to the circulating strain. It hasn't been proven in a clinical trial because we don't

have time to do a clinical trial because we need to get the vaccine out now because we have such

a situation throughout the world and certainly in the United States.

I mean, what's the next step? We talked about this last week. We talk about this really every week,

but it's amazing this idea that and what I want people to focus on, they keep talking about efficacy,

right? They want you thinking about we have every reason to believe that if we attack Omicron,

the vaccine will be better at doing what it's doing than using the old one. Well, the old one sucked

against the virus that it was trying to stop, didn't do it. Everyone's gotten sick. Two, three times,

more and more studies showing you're going to get sick, more often if you get the vaccine. But where's

the safety, right? We skipped all the safety trials, which is what we've always been focused on the

high wire. I don't care about efficacy. Is this thing safe? We have absolutely no idea. Then now,

based on the fact that you skipped the safety trials, called again emergency use authorization,

then as soon as you got that authorization, you erased your entire placebo group by saying,

hey, I'm not going to have them get the vaccine. So you knew what you were doing. You erased that

group. Then now we're just going to say, hey, we don't have time to do safety studies at the next

ones. And we're going to run off of the science that was done in the first ones, which was not

...